Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Apr 24:13:130.
doi: 10.1186/s12967-015-0491-3.

Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases

Corrado Boni  1 , Maria Pagano  2 , Licia Baldi  3 , Roberta Gnoni  4 , Luca Braglia  5 , Luisa Savoldi  6 , Francesca Zanelli  7
Affiliations
Observational Study

Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases

Corrado Boni et al. J Transl Med. .

Abstract

Objectives: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in overall survival (OS) has been done in the last 25 years, with Cisplatin-Etoposide (PE) still considered the world-wide standard, with an average median survival of about 7-8 months in patients with extended disease (ED). In 1995, a randomized trial of the Hoosier Group in 171 ED patients showed a significant advantage in overall survival in patients treated with PEI (Cisplatin, Etoposide and Ifosfamide), compared to PE. Despite that, PEI regimen has not become a commonly used regimen in SCLC.

Materials and methods: Here we present a retrospective analysis of 46 consecutive patients (30 males and 16 females) with SCLC that were treated at our Institution with PEI regimen: Cisplatin 20 mg/m2, Etoposide 75 mg/m2 and Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks. Patients received a total of 219 cycles of chemotherapy, with a mean of 4,7 cycles per patient. Median age was 63 (range 59-70); performance status (PS) was 0 in 29 patients (63%), 1 in 13 patients (28%) and 2 in 4 patients (9%).

Results: In 19 limited disease (LD) patients partial response (PR) rate was 74%, and complete response (CR) was 16%. In 27 ED patients we observed 63% of PR and 26% of CR. Median time to progression (TTP) was 15.2 months in LD and 7.1 months in ED with median overall survival (OS) of 28.2 and 11.8 months, respectively. Toxicity was manageable, with a high dose intensity.

Conclusions: PEI regimen, in our opinion, may be a possible therapeutic option, with high activity and an acceptable toxicity profile.

Trial registration: ClinicalTrials.gov Identifier: NCT02324296 .

Institutional review board that approved the study: Institutional review board of Reggio Emilia, Azienda Ospedaliera S.Maria Nuova/IRCCS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival in limited and extended disease.
Figure 2
Figure 2
Time to progression in the limited and extended disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Cancer Society . Cancer facts and figures 2012. 2012.
    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44. doi: 10.1200/JCO.2005.04.4859. - DOI - PubMed
    1. Hochstenbag MM, Twijnstra A, Wilmink JT, Woutes EF, Velde GP. Asymptomatic brain metastases (BM) in small lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000;48:243–8. doi: 10.1023/A:1006427407281. - DOI - PubMed
    1. Sorensen M, Pijls-johannesma M, Felip E, for the ESMO Guidelines Working Group Small- cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up-up. Ann Oncol. 2010;21(suppl 5):v120–5. doi: 10.1093/annonc/mdq172. - DOI - PubMed
    1. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8. doi: 10.1016/S0140-6736(05)76153-5. - DOI - PubMed

Publication types

Associated data